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ELECTROCHEMICALLY CONTROLLED RELEASE OF DEXAMETHASONE 
FROM CONDUCTING POLYMER POLYPYRROLE COATED ELECTRODE 
 
 Reecha Wadhwa, M.S. 
University of Pittsburgh, 2006
 
Chronic recordings from micromachined neural electrode arrays often fail a few weeks after 
implantation primarily due to the formation of an astro-glial sheath around the implant.  We 
propose a drug delivery system, from conducting polymer (CP) coatings on the electrode sites, to 
modulate the inflammatory implant-host tissue reaction.  In this study, polypyrrole (PPy) based 
coatings for electrically controlled and local delivery of the ionic form of an anti-inflammatory 
drug, dexamethasone (Dex), was investigated. The drug was incorporated in PPy via 
electropolymerization of pyrrole and released in PBS using cyclic voltammetry (CV).  FTIR 
analysis of the surface showed the presence of Dex and polypyrrole on the coated electrode.  The 
thickness of the coated film was estimated to be ~50 nm by ellipsometry.  We were able to 
release 0.5 µg/cm2 Dex in 1 CV cycle and upto 92% Dex after 30 CV cycles.  In-vitro studies 
and immunocytochemistry on murine glial cells suggest that the released drug lowers the count 
of reactive astrocytes to the same extent as the added drug.  In addition, the released drug is not 
toxic to neurons as seen by healthy neuronal viability in the released drug treated cells.   
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1.0  INTRODUCTION 
Neural prostheses are implantable microelectronic devices used to bypass, repair or restore 
damaged neurological function by electrical stimulation or recording from the peripheral and 
central nervous systems.  The chronic application of these devices has been limited by their 
unpredictable failure over extended periods.  Although the precise mechanism for this failure is 
not completely known, it is suggested that an undesirable brain tissue reaction to the device leads 
to the formation of a glial scar which then serves as a barrier to neural signal transduction [1-8]. 
Biomaterials strategies are being explored to minimize or eliminate the undesired tissue 
reaction. Two major directions are being taken, one being enhancing neuronal growth and 
adherence to the electrodes via immobilization of biomolecules on electrode surface or through 
release of growth factors or chemo-attractants from the electrodes[9-17], and the other being 
mitigating the brain microenvironment through delivery of anti-inflammatory factors in the 
vicinity of the implant.  Dexamethasone (Dex) is a synthetic glucocorticoid anti-inflammatory 
drug which can reduce inflammation in the Central Nervous System (CNS).  The drug is 
believed to act through its glucocorticoid receptors found in most neurons and glial cells 
throughout the brain [18].  These receptors’ pathways are involved in the inhibition of astrocyte 
proliferation [19] and microglial activation [20].  Additionally, as an anti-inflammatory 
substance, Dex reduces numerous pro-inflammatory cytokines, including IL-1β, IL-6, INF-γ and 
TNF-α [21].  Peripheral injections of Dex have been shown to effectively minimize the reactive 
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tissue response to neural implants in the rat [22].  However, systemic injections have the obvious 
disadvantage of exposing the whole body to high dosages of the drug and its potential toxicity.  
Local delivery of drugs at the implant/tissue interface would be most effective.  Dexamethasone 
eluting coatings are being developed [23, 24].  The release of Dex from these coatings, indeed, 
decreased the degree of reactive tissue response of the brain implants as shown in 
immunohistopathological studies.   However these passive drug eluting coatings can not last as 
long as needed in applications such as cortical prostheses nor can they release appropriate doses 
in response to the dynamic change of the local biochemical environment.  A microfluidics-based 
drug injection system is also being investigated for the same purpose, wherein intracortical 
probes with microfluidic channels are fabricated and tested to understand the possibility of using 
diffusion-mediated delivery to deliver therapeutic agents into the immediate surroundings of the 
implanted devices [25].  Convective delivery is also plausible and this method can theoretically 
incorporate components such as pumps and valves for active control of the release.  However, 
the current fabrication technology has not demonstrated the precision needed for sub-picoliter 
delivery.  Furthermore, adding more components to the neural electrode arrays means more 
processing steps, more failure points and less reliability.  
Conducting polymers have the ability to undergo reversible red-ox reaction under the 
stimulus of an electrical potential. The doped polymer film can be electrically switched between 
the oxidized state and reduced state [26].  The red-ox reaction involves charging and discharging 
of the polymer and is also accompanied by the movement of hydrated ions in and out of the bulk.  
Utilizing this feature, efforts have been made to develop delivery systems in which conducting 
polymers can be loaded with some chemical substances (drug, growth factors) and the loaded 
dopants can be released in response to electrical stimulus.  The anionic drugs salicylaten, 2-
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ethylhexylphosphate (EHP) and naproxen and the cationic drug dopamine have been 
incorporated into conducting polymer membrane and released by electrical potential stimulus in 
a controlled way [27-29].  Adenosine triphosphate (ATP) was shown to be released from 
polypyrrole upon sensing bioactive molecules in the solution [30].   
Polypyrrole and its derivatives are the most widely used conducting polymers in 
biomedical applications due to their biocompatibility and customizability [31-36].  Polypyrrole 
has been electrically deposited onto the electrode site of the neural recording arrays together with 
CDPGYIGSR, a peptide fragment from laminin [9, 37], to improve the neuron-electrode 
connection in vivo.   
In the current study, polypyrrole (PPy) based electrode coating for controlled and local 
delivery of the ionic form of an anti-inflammatory drug, dexamethasone (Dex), was investigated.  
The drug incorporation was done using a one-step electropolymerization.  The release of the 
drug was carried out using cyclic voltammetric stimulus and was found to be precisely 
controllable i.e. the released amount was linear to the number of applied stimuli.  The released 
dexamethasone showed anti-inflammatory effects by lowering number of reactive astrocytes in 
vitro.  In primary neuronal culture, healthy neuronal growth was observed in the drug treated 
cultures, indicating that the delivery mechanism does not produce any toxic leachables and that 
the drug does not damage neurons at this dosage.   
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2.0  INCORPORATION OF DEX IN PPY-DEX FILMS ON GOLD ELECTRODES 
2.1 INTRODUCTION 
The first sets of experiments were conducted to incorporate the drug in the polymer films on the 
model gold electrodes.  Gold coated coverslips were prepared and PPy-Dex films were deposited 
using one step electropolymerization.  Upon deposition the films were analyzed using Fourier 
Transform Infrared Spectroscopy (FTIR), Ellipsometry and Atomic Force Microscopy (AFM). 
Details of these experiments are described in this chapter. 
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2.2 MATERIALS AND METHODS 
2.2.1 Electrodeposition of Polypyrrole-Dex Coating  
2.2.1.1 Electrode preparation 
22 mm plastic coverslips (Fisher) were cut to uniform dimension of 7 mm x 22 mm, cleaned with 
8N HNO3 for 30 min, washed in deionized H2O and stored in ethanol.  In order to create a 
conductive surface for electrochemical deposition, the cut and cleaned coverslips were sputter 
coated with a layer of gold, using a Cressington Sputter Coater.  The thickness of the gold layer 
was approximately 40 nm.  The gold coated coverslips (electrodes) were stored in a desiccator. 
 
2.2.1.2  Electrochemical deposition 
PPy / Dex film was grown potentiostatically on the gold coated coverslips.  A two electrode set 
up was used.  The electrochemical cell was a 2 ml glass cuvette containing a working electrode 
(gold coated coverslip with or without the polymer-drug coatings) and a platinum counter 
electrode.  The coating process was controlled using the Gamry Potentiostat, FAS2/Femostat 
(Gamry Instruments) with Gamry Framework software.  The deposition solution (1 ml) 
contained 0.1 M pyrrole (Sigma) and 0.1 M dexamethasone disodium phosphate (Sigma).  The 
actual electrode area immersed in the solution was ~0.77 cm2, which is the area covered by the 
resulting polymer-drug film.  In the potentiostatic mode, a constant potential of 1.8 V relative to 
the counter was used.  The amount of material deposited on the electrode surface was controlled 
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by time via the total charge passed during deposition.  A range of deposition charge densities (15 
-120 mC/cm2) were investigated.  25-30 mC/cm2 was found to be optimal in terms of film 
stability and release efficiency, and was therefore selected for the rest of the study. 
2.2.2 Fourier Transform Infra Red Spectroscopy (FTIR) 
IR spectroscopic measurements were carried out using the Continnum IR microscope (Thermo-
Nicolet).  The detector was cooled with liquid nitrogen before use and the entire system was 
purged with in-house air at a flow rate of about 25 standard cubic feet per hour.  The coated 
coverslips were placed on the microscope stage and the reflective IR spectrum was collected.  
The samples were scanned 200 times in the range of 1000-4000 cm-1.  The spectrum of a clean 
gold coverslip was used as the background.  The spectra were analyzed using the software 
OMNIC. 
2.2.3 Ellipsometry 
The PPy-Dex film thickness was measured with a Gaertner L-117 Null ellipsometer.  A linearly 
polarized He-Ne laser with wavelength 632.8 nm was used in the measurement at incident angle 
70º.  The analyzer (A) can detect the change in the phase angle (Δ) and the amplitude change (Ψ) 
of the light after reflection from the sample.  Refractive indices of n1=1 for air, n2=1.45 [38] for 
the organic molecular monolayer, and n3=0.166+3.22i for gold were used to calculate the 
thickness of the films using the equation, )exp(tan Δ== i
r
r
s
p ψρ                         
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where ρ is the ratio of Fresnel Reflection Coefficients rp and rs and within it contains the 
thickness term.    
2.2.4 Atomic Force Microscopy (AFM) 
Information about the sample surface topography was obtained with Atomic Force Microscopy 
(AFM) and Scanning Electron Microscopy (SEM).  AFM was performed with a MFP3D TM 
inverted optical model Atomic Force Microscope (AFM) (Asylum Research, Santa Barbara, 
CA).  For each condition, four samples were used and eight images per sample taken.  The 
images obtained consisted of 256X256 arrays of height data over a scan size of 10 μm and a scan 
rate of 1 Hz.  Data were collected in tapping mode using a cantilever tip with height of 15-20 µm 
and radius of < 10 nm.  Surface scans from the AFM were analyzed using IGOR Pro5.03 
(Wavemetrics, OR, U.S.A) and MFP-3D Xop software version 050126.   
2.3 RESULTS AND DISCUSSION 
A one step electropolymerization was used to deposit films of PPy and Dex on the surface of 
gold coated electrodes.  The underlying principle of electropolymerization of PPy is shown in 
figure 1.  In presence of a dopant A- (anions or negatively charged biomolecules or drugs), the 
monomers become electrically oxidized and polymerized and the resulting polymer gets 
deposited on the anode.  Because the polymer backbone is positively charged, the anionic dopant 
molecule is incorporated to maintain charge neutrality.  In our case the dopant was 
dexamethasone disodium phosphate (Dex), a synthetic glucocorticoid which acts as a pro-drug 
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and can get converted into the active dexamethasone [41].  The chemical structure of the pro-
drug is shown in figure 2.  The presence of a phosphate group on the dexamethasone steroid ring 
structure imparts a negative charge to the drug, which can then be incorporated as a dopant in 
PPy following electropolymerization.   
 
The deposited film was characterized qualitatively by FTIR spectroscopy.  The result is 
presented in figure 3.  From 1800 to 4000 cm-1, the spectrum showed a continuous increase in 
absorption.  This is the tail of the ~1 eV (~8066 cm-1) bipolaron absorption band, which is the 
signature for electrical conductivity of conducting polymers [42, 43]. The broad band around 
1550 cm-1 is the characteristic absorption frequency for double bond vibration of the pyrrole ring 
[9, 37, 44, 45].  Proof of the presence of dexamethasone in the deposited film is clearly seen by 
the appearance of peaks at 3200-3500 cm-1 (hydroxyl), 2850-3000 cm-1 (methyl) and 1665-1760 
cm-1 (carbonyl).  These groups can be identified in the chemical structure of dexamethasone. 
 
The thickness of the deposited film was detected using ellipsometry.  The average 
thickness was found to be 50 nm for the films deposited at charge density of (~ 30 mC/cm2).  
The surface morphology of the PPy-Dex was revealed by tapping mode AFM as shown in figure 
4.  For a deposition charge density of 30 mC/cm2, the films appear smooth.  The root mean 
square roughness (RMS) value was 12 nm.  Increasing the deposition charge density to about 
120mC/cm2 resulted in a drastic increase in surface roughness.  The RMS value was measured to 
be about 95  nm.  The films deposited at higher charge density did not appear to be uniform, with 
some areas being rougher or smoother than others.   
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2.4 CONCLUSION 
PPy-Dex films were successfully grown on gold coated coverslips using electrochemical 
deposition techniques.  The incorporation of the drug in the polymer films was confirmed by 
surface detection, of Dex in PPy-Dex films, using FTIR.  The films were further characterized 
using ellipsometry and AFM analysis.   
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Figure 1.  Principle of electropolymerization of polypyrrole.    
The negatively charged dopant (A-) is incorporated into the positively charged polymer backbone to maintain 
electrical neutrality.   
 
 
 
 
Figure 2.  Chemical Structure of disodium salt of dexamethasone 
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Figure 3.  FTIR spectrum of the PPy-Dex polymer coatings on electrode.   
The presence of Dex on the surface is indicated by peaks at (a) 3200-3500 cm-1 (hydroxyl), (b) 2850-3000 cm-1 
(methyl) and (c) 1665-1760 cm-1 (carbonyl) in the spectrum.  No such peaks were obtained in the PPy-Cl– films, as 
seen in the second curve.  Characteristic broad peak for polypyrrole appears at (d) 1550-1650 cm-1.  
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Figure 4.   AFM images for the PPy-Dex coated electrode surface. 
 (a) 30 mC/cm2 (RMS ~12 nm) and (b) 120 mC/cm2 (RMS ~ 95 nm).  As the electropolymerization time increases, 
the film becomes rougher. 
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3.0  DEXAMETHASONE RELEASE STUDIES  
3.1 INTRODUCTION 
The previous experiments established that dexamethasone was indeed deposited in the PPy-Dex 
films on the electrodes.  The next logical step was to study the amount of dex released upon 
application of electrical stimuli.  Cyclic voltammetry (CV) was the chosen type of stimuli, 
wherein the potential was swept between positive and negative values periodically.  The film 
surface before and after release was analyzed by scanning electron microscopy (SEM) and 
optical microscopy.  Impedance measurements were used to evaluate the electrical behavior of 
the film.  The released drug was quantified using ultraviolet spectroscopy.  The details of these 
experiments are described in this chapter.   
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3.2 MATERIALS AND METHODS 
3.2.1 Scanning Electron Microscopy (SEM) 
The PPy/Dex film surface morphology before and after drug release was studied under SEM.  A 
JEOL 9335 Field Emission Gun SEM was used with a typical voltage of 10 kV.   A thin film of 
gold/ palladium (3.5 nm) was sputtered onto the specimens using a Cressington Sputter Coater, 
before the surfaces were viewed.   
3.2.2 Optical Microscopy  
An optical microscope (Axioskope 2 MAT, Carl Zeiss) was employed to visualize the changes in 
morphology of the film after drug release.  The images were taken using AxioCamMRC5 
Camera (Carl Zeiss) attached to the scope.  The images were taken and analyzed using 
AxioVision Rel 4.2 software.  
3.2.3 Cyclic Voltammetry 
Cyclic voltammetry (CV) was performed using Gamry Potentiostat, FAS2/Femostat (Gamry 
Instruments) under the software control of Gamry Framework  For drug release studies, the CV 
was done in the two electrode cell described in 2.1.2  and the electrolyte was PBS (0.1 M, pH 
7.2).  The voltage was swept from -0.8 V to +1.4 V at a scan rate of 100 mV/s.  Dex release was 
quantified by UV absorbance (detail see 2.5) after every five cycles till thirty cycles.  Before 
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beginning CV, the coated electrodes were soaked in distilled water to remove any loosely 
attached dexamethasone on the surface.  This ensured that the release of Dex is caused mainly by 
the cyclic potential stimulus.  A control was set up, in which the coated electrode was simply 
soaked in the PBS solution without electrical connection.  UV reading of the solution was taken 
six successive times at time intervals of five minutes, to compare with the six sets of five CV 
cycles (5 CV cycle ~ 5 minutes at 100  mV/s).  To study long term diffusion of Dex, if any, UV 
measurements were also taken after a 24-hour soaking.   
3.2.4 Ultraviolet (UV) Spectroscopy 
The released drug was detected using UV spectrometer (Genesys 5 TM spectrophotometer, 
Thermospectronic).  The readings were taken at 242 nm, the characteristic absorbance band of 
Dex.  Double distilled water was used as blank and the reading of PBS alone was subtracted 
from the reading for released sample.  A standard calibration curve for Dex was plotted to define 
the quantitative relationship between observed absorbance and concentration of Dex.  
3.2.5  Impedance Measurements 
Electrochemical impedance spectroscopy was done using the Gamry Potentiostat, 
FAS2/Femostat, under the control of the Gamry Framework software.  A solution of 0.1 M PBS 
buffer (25 ml) (pH = 7.2) was used as the electrolyte in a three-electrode cell. A platinum foil 
was used as the counter electrode, a saturated calomel electrode (SCE) was used as the reference 
electrode and the gold coated electrode with or without polymer coatings was used as the 
working electrode.  AC sinusoid signal of 5 mV amplitude, with the DC potential set to 0 V was 
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used as the input.  The value of the impedance was determined at four discrete frequencies per 
decade over the range of 10 to 105 Hz.  
3.2.6  Statistical Analysis  
Statistical analysis was performed in SPSS.  For comparisons involving multiple groups, 
ANOVA followed by Bonferroni’s post-hoc analysis was used.   
3.3 RESULTS AND DISCUSSION 
The fundamental principle behind our drug release is explained as follows.  
 [(PPy)x+(A-)x]                        PPy + xA- 
 
Here A- is the dopant.  The movement of ions in or out of the polymer film forms the 
basis of drug delivery with polypyrrole.  In our experiments, alternating positive and negative 
potential was applied using cyclic voltammetry to release the anionic Dex from the PPy-Dex 
film.  The change of oxidation state is supported by the cyclic voltammogram (figure 5).  Cyclic 
voltammetry provides information about the intrinsic redox reaction of the electrode materials as 
the potential of the electrode is swept in a cyclic manner.  The cyclic voltammogram is a plot of 
the measured current against the applied voltage at the working electrode vs. the reference 
electrode.  Polypyrrole is known to have switching properties and this is evident by the 
appearance of characteristic anodic and cathodic peaks as seen in figure 5.  It is to be noted that 
during the first 2-3 CV cycles these peaks were not seen.  However, as the number of CV cycles 
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increase, the peaks become evident.  The figure shows appearance of characteristic oxidation and 
reduction peaks at +0.49 V and -0.34 V respectively.  The reduction peak is an indication of the 
release of the drug.  The absence of peaks in the first 2-3 cycles indicated that the film needed to 
be rejuvenated before drug release starts.   
 The release of Dex in solution was quantified using UV spectrometry at 242 nm.  The 
released amount triggered by CV stimulus is displayed in figure 6.  It is evident from the graph 
that the release of Dex correlated in roughly linear fashion (R2 = 0.9964) with the number of CV 
stimulus in the given CV cycle range.  As a control, UV readings were taken from coated 
electrodes dipped in PBS to which no electrical stimulus was applied.  As expected, there was no 
significant release of Dex from these control samples by diffusion.  As diffusion is a time 
dependant process, we also took readings after 24 hours and saw no significant Dex release.  The 
above observation indicates that our system is a true electrically controlled release system.   
Estimates of the amount of drug deposited in the film were obtained using the following 
governing equation [46] 
−++ +++→ exHPPyPy x )2(2)(   
dep
cap
Q
Q
x
x =+2   
where, Qdep is the deposition charge and Qcap is the charge capacity under 1 CV cycle.  
For Qdep = 20 mC and Qcap = 2.5 mC, we can load nearly 17.4 µg/cm2 of Dex in the PPy-Dex 
film.  We are thus able to achieve 92% drug release at the end of 30 CV cycles.   
Previous research has shown that dexamethasone is effective at a concentration of 0.2-0.7 
µM [47] and around this local concentration, pronounced reductions in inflammatory tissue 
reactions are seen around neural implants.  We are able to release 0.5 µg/cm2 Dex after each CV 
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cycle and to a total of nearly 16 µg/cm2 after 30 CV cycles.  Based on most of the histological 
studies, the reactive region indicated by enhanced glial fibrillary acidic protein (GFAP), a key 
intermediate filament, activity around the neural electrode arrays has a radius of less than 500 
µm [7, 48].  A release of 0.5 µg/cm2 Dex will result in average Dex concentration of 1 µM 
within 500 µm radius from the electrode.    Thus, 1 dose triggered by 1 CV may be sufficient to 
reduce the inflammation and with successive CV cycles the concentration of Dex remains in the 
µM range and can be expected to eliminate adverse tissue reaction to the electrode in long term.  
Certainly, the in vivo situation may be different from our theoretical estimation. The actual 
efficiency and appropriate dosage of Dex will only be determined in the in vivo studies. 
It should be pointed out that we also examined the UV absorption at 210 nm, the 
maximum UV absorbance band of pyrrole, and found that there was a minute amount of pyrrole 
monomer in the solution after the release.  Fortunately, the contribution of pyrrole to the 242 nm 
absorbance, used for quantification of Dex, was negligible.  The in vitro data also demonstrated 
that the leached pyrrole was not toxic to the cultured cells. 
Most of the previously reported polypyrrole based molecule release systems utilize step 
potential stimuli (positive or negative depending on the charge of the ions to be released). The 
released dosage was found to be a function of time (time of applied potential stimuli).  The step 
function was used initially in our preliminary studies, and was found to be less effective than 
cyclic potential stimuli towards drug release. The two release mechanisms will be analyzed and 
compared as follows. 
In the case of step potential stimulation (for example with small anionic release), a 
negative potential reduces the polypyrrole, neutralizes the positive charge on the backbone and 
eliminates the electrostatic bonding between polypyrrole and its anionic dopants.  The 
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dissociation of the dopants from the polypyrrole chain may be an instant process, but the release 
of the anion is slow since it is driven by diffusion consisting of movement of anions from the 
inner film to the surface and from the surface to the solution.  For dense films, as in our studies, 
the former is much slower, and hence the quick release is mainly from the surface, and the bulk 
release may take hours.  In addition, under the applied negative potential, the reduced film will 
become electrically non-conductive.  The longer the film is held at a negative potential, the more 
difficult it is to recover its conductivity after the stimulus is removed.  Such a system is not ideal 
in most of the practical application when electrodes have other functions to perform. 
In the case of cyclic potential stimulation, the film undergoes a fast swelling and 
deswelling process caused by ion and water movement in and out of the film [49-51]. This 
process may act as a pump to push the anions out and dramatically speed up the bulk release 
(seconds or minutes).  When the potential is being swept at a high speeds (100 mV/sec, in our 
case), only a portion of the dopants are dissociated and pumped out during each cycle.  This 
forms the basis of linear correlation between released dose and number of cyclic stimulus, ideal 
for on command dose controlled release.  In addition, without application of a long potential 
bias, the polymer film can remain conductive after each release stimulus, consequently the 
electrode remains functional.  
Several observations provide support for the above mechanism.  First, a closer look at the 
deposited film surface before and after release was taken under SEM.  Figure 7 shows that before 
release the film appears essentially smooth.  After 50 CV cycles, however, there were 
appearance of cracks.  This breakdown of the film starts to appear after ~30 CV cycles.  This 
suggests that the polymer-drug film indeed undergoes physical changes of swelling and de-
swelling during the CV cycles which causes its delamination and breakdown.  Also, higher 
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charge density resulted in rougher films (shown in figure 4b) but not higher drug release, which 
further provides evidence that the drug release triggered by the electrical stimulus (CV) occurs 
from within the film and was not a surface phenomenon.   
The film morphology before and after CV stimulated release was also analyzed using 
optical microscopy, as shown in figure 8.  A change in color of the film induced by CV cycles 
was observed and it appeared to be darker in color than the original PPy-Dex film.  The color of 
the film reflects its oxidative state and configuration of the polymer/dopants complex.  This color 
change indicated that the film underwent structural and compositional changes during the course 
of CV treatment and the accompanying Dex release.   
The electrical properties of the film were evaluated using impedance measurements.  
Impedance is a complex quantity defined as Z (ω) ≡ |Z(ω)| eiθ(ω) ≡ v(ω) / i (ω), where v(ω) is the 
transform of an alternating potential signal applied to the system and i(ω) is the transform of the 
alternating current signal that results.  The impedance is characterized by a magnitude (|Z|) and 
phase angle (θ), and is generally represented as a function of frequency.  Impedance 
spectroscopy involves measuring the electrode impedance over a spectrum of frequencies.  
Impedance spectroscopy is often used in neural electrode analysis for characterizing 
electrode/tissue or electrode/solution interface.  So it is a relevant technique to be used here to 
examine the effect of deposited PPy/Dex on the bare electrode.  The results are displayed in 
figure 9.  The impedance of the freshly made coated electrode is higher than the uncoated gold 
electrode at all frequencies.  However, the impedance dropped immediately after the first few 
CV cycles.  The impedance magnitude was lower than that of gold in the lower frequency range 
and it continued to be lower for the rest of the 30 CV cycles.  It appears that the polymer-drug 
film is not as conductive initially, and perhaps was left at a reduced state immediately after 
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deposition.  Rejuvenation through a few CV cycles can activate the film and make it more 
conductive.  This rejuvenation may result from exchange of bulky Dex molecules with smaller 
anions like H2PO4- and  HPO42-, and Cl- from PBS,  causing an increase in conductivity of the 
deposited film.  Once in the more conductive state, the impedance becomes lower than bare gold, 
a commonly seen phenomenon in conducting polymer electrodes due to the higher surface area 
and more efficient charge transport of the polymer coating [52, 53].  This is important since 
having low impedance is beneficial in recording minute extracellular neural signals.   
3.4 CONCLUSION 
Dex release from PPy-Dex films on gold coated coverslips was carried out using CV technique.  
A linear release profile was seen on application of successive CV cycles and we were able to 
successfully release 92% of the incorporated drug into PBS after 30 CV cycles.  Surface 
characterization using SEM demonstrated that the polymer film starts to break down beyond 30 
CV cycle.  The optical microscopy images show change in color of the polymer film before and 
after drug release, indicating the structural and chemical changes in the film due to application of 
CV stimuli.  Impedance studies also supported these observations, as indicated by lowered 
impedance after application of CV stimuli.   
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 Figure 5.  Characteristic Cyclic Voltammogram. 
At the 2nd CV cycle no peaks are observed, implying there is no sudden release of drug and that the first few cycles 
are used to ‘rejuvenate the film’.  Anodic and cathodic peaks begin appearing in the following CV cycles.  At 25 CV 
cycle, characteristic oxidation peak (anions move in) (a) and reduction peak (anions including Dex move out) (b) are 
evident.   
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 Figure 6.  Release profile of Dex from the polymer-drug coated electrodes. 
The release of Dex (n= 5, ± SEM) was detected using UV spectroscopy at 242 nm.  The drug release is 
approximately linear.  For PPy-Dex, the x-axis represents number of CV cycles.  Control was set up to study the 
release from the film in the absence of any electrical stimulation.  In this case the x-axis represents the number of 
minutes (at 100 mV/sec scan rate, 1 CV cycle between -0.8 V to 1.4 V takes approximately 1 minute). There is 
negligible release, possibly due to diffusion of loosely attached dex from the surface.  
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 Figure 7.  SEM images 
(a) PPy-Dex coated film (b) PPy-Dex film after 50 CV cycles.  The SEM shows smooth surface for the deposited 
films.  Cracks become evident after ~30 CV cycles.  These are prominently seen in (b) after 50 CV cycle. 
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 Figure 8.  Enface image of the gold polymer interface under optical microscope 
Initial CV cycles rejuvenate the polymer surface and the surface appears darker in color than the original PPy-Dex 
coating.  The dark color corresponds to oxidized state of the film.   This change in color reflects a change in the 
chemical configuration of the polymer film. 
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 Figure 9.  Impedance spectroscopy for gold and PPy-Dex film coated electrode. 
Initial impedance of the film is very high.  But after the first few CV cycles, the impedance drops at all frequencies 
and at the lower frequency range, the magnitudes are lower than those of the gold electrode.  This implies deposited 
film was in its reduced state and needed ‘rejuvenation’, which was provided by initial CV cycles.  The lowered 
impedance is maintained till 30 CV cycles.   
 
 
 
 26 
4.0  IN VITRO CELL CULTURE STUDIES 
4.1 INTRODUCTION 
After the release profile of dexamethasone from PPy-Dex films on our gold electrodes was 
established, testing for the efficacy of released drug was the next step. For the in vitro studies, 
primary murine cerebellar cells were cultured using the techniques described in this chapter.  The 
effect of released dexamethasone on both astrocytes and neurons was studied using 
immunohistochemistry and the analysis was done using optical microscopy and imaging.   
4.2 MATERIALS AND METHODS 
4.2.1 Primary neurons and astrocytes cell culture 
Primary murine neuronal cultures were prepared as described by Schnitzer et al [39]. Briefly, 
following trypsinization and trituration, the cells were pelleted to remove debris and resuspended 
in DMEM with 10% horse serum (HyClone).  These resuspended cells were plated on polylysine 
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(Sigma; >400,000kD) coated glass coverslips (Fisher) at a cell density of 30,000 cells per 12mm 
diameter coverslip.  Glial cultures were prepared using the protocol of Banker G and Goslin K 
[40].  Briefly, astrocyte and microglial cells were harvested, trypsinized, triturated and then 
plated using Dulbecco’s modified eagle medium (DMEM), with 10% fatal calf serum (FCS) at 
37oC with 5% CO2 , until confluent.  These glial cultures were then trypsinized and replated on 
polylysine-coated coverslips.  The cells were allowed to settle on the coverslips for 30 minutes 
and treated with three groups of media - control (DMEM + 10% FCS), Dex (DMEM +10% FCS 
+ 10-6 M Dex) and DexR (same as Dex, except that the Dex was released in PBS from the 
electrode coating and then added to the media at 10-6 M concentration).  Cells were kept in the 
incubator at 37° C and 5% CO2 and analyzed on day 3 for astrocytes count.  The neuronal cells 
were treated with control, Dex and DexR media and assayed for neuronal viability and growth on 
day 3.   
 
4.2.2  Immunocytochemistry 
Immunochemical labeling was done using antibodies against a neuronal  
marker, class III β-tubulin (Covance) and an astrocyte-specific marker, Glial Fibrillary Acid 
Protein (GFAP) (Dako).  Cells were fixed with 4% paraformaldehyde for 10 minutes.  In 
neuronal culture, cells were treated with 1% NP40 (CalBioChem) in 4% paraformaldehyde for 
10 minutes at room temperature.  Nonspecific binding was blocked by incubation with blocking 
buffer (0.5% bovine serum albumin and 10% horse serum in TBS).  Primary and secondary 
antibodies were added for one hour each.  Following immuno-staining cells were counterstained 
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using the nuclear dye Hoechst 33258 (2 mg/ml in PBS) (Sigma).  A similar protocol was 
followed for staining astrocytes.  
 
4.2.3 Imaging and analysis 
After immunostaining, digital images were taken using the fluorescence microscope (Axioskop 2 
MAT, Carl Zeiss) using AxioCamMRC5 Camera (Carl Zeiss) attached to the scope and software 
AxioVision Rel 4.2.  For neuronal cell culture, the neurite measurement feature of MetaMorphTM 
software was used.  The software utilizes the values specified for various parameters i.e. cell 
body (width, minimum area, intensity above background), nuclei (minimum width, maximum 
width and intensity above background) and outgrowth (maximum width, intensity above 
background and minimum growth to log as significant) to accurately map the neurite outgrowth 
from fluorescent images.  Healthy neurons were counted as those with at least one neurite and 
which showed co localization of β-tubulin and Hoescht stain.  The cell counts on the astrocytes 
images was done manually by identifying GFAP staining co-localized with a Hoechst stained 
nuclei.  For the neuronal culture, six coverslips were used for each condition (Ctrl, Dex, and 
DexR) and six images were taken for each coverslip at 20X magnification.  For the astrocytes 
culture experiments, three coverslips were used for each condition and six images were taken for 
each coverslip at 10X magnification.  In both cases the experiment was repeated twice.    
 
 29 
4.2.4 Statistical analysis  
Statistical analysis was performed in SPSS.  For comparisons involving multiple groups 
(astrocytes count studies), ANOVA followed by Bonferroni’s post-hoc analysis was used.  For 
the neuronal cell culture experiment, n=6×2 and for the astrocytes culture, n=3×2.  p values 
< 0.05 were considered as significant.   
4.3 RESULTS AND DISCUSSION 
To study the effect and efficacy of the released Dex, in vitro studies were conducted with 
primary murine cerebellar glial culture.  Immunostaining with antibodies against GFAP revealed 
lowered number of reactive astrocytes in Dex treated samples when compared to those in control 
media on day 3 (figure 10a-c).    In figure 10d, the day 3 astrocyte counts are represented after 
being normalized to the day 1 control.  On day 3, the number of astrocytes in the control group 
almost doubled, while both the Dex added and Dex released groups showed significantly fewer 
astrocytes.  In addition, there was no significant difference between the Dex added group and 
Dex released group, which implies that the released Dex was as effective as the added Dex From 
these studies we cannot determine if this is due to reduced proliferation or enhanced cell death. 
Preliminary work with microglia cells also showed lowered growth of cells, as indicated in 
figure 11.  It is to be noted here that due to shortage of appropriate antibody for the microglia 
cells, the experiment with microglia cells could be done only once.     
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The released Dex may serve two purposes.  Firstly, it decreases the number of reactive 
astrocytes.  Astrocytes are a major component of the insulating glial sheath formed during the 
inflammatory response against the electrodes, when implanted in vivo.    The objective therefore 
was to prevent them from getting into their reactive state and our in vitro data proves that the 
released Dex showed such effect.    
 
Secondly, the drug shows a positive impact on neurons at this concentration as well. 
Figure 12 shows the effect of Dex on the viability of neurons on day 3 for control (Ctrl) added 
Dex (Dex) and released Dex (DexR).  There is no significant difference in the number of neurons 
in the control, Dex or DexR.  This implies that the released drug at this concentration is not toxic 
to neurons.  We also observed 35% higher neurite outgrowth in cells exposed to released Dex 
than those in control.  These observations collectively indicate that the released drug may have a 
neuroprotective effect.  Whether dexamethasone acts directly on its receptors in neurons or 
indirectly through its anti-inflammatory mechanism via astrocytes and microglia is not yet clear, 
though literature suggests an indirect mechanism [54].  Neurodegenerative diseases like 
Alzheimer’s disease and Parkinson’s disease are often accompanied by inflammatory reactions.  
In vivo studies in mouse models have demonstrated that intraperitoneal injections of Dex may 
exert a neuroprotective effect towards injured neurons, but only in proper doses [54].  While 
higher doses of Dex may be toxic to neurons, a lower dose has proven to have a neuroprotective 
effect in those experiments.  A similar mechanism may explain the higher neurite outgrowth seen 
in our experiments.  
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4.4 CONCLUSION 
In vitro studies were successfully conducted to study the effect of released Dex on astro-glial 
cells and neurons.  The drug was shown to maintain its anti-inflammatory properties, upon 
electrochemical release from the PPy-Dex films, as seen by lowered reactive astrocyte count.  
Also, at the released concentration no toxic effect of Dex was seen on the cultured neurons, as 
indicated by healthy neuronal count.   
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Figure 10.  In-vitro studies for the effect of Dex on reactive astrocytes number 
The red color is GFAP staining.  The nuclei are stained using Hoechst dye.  (a) Control group: no drug, (b) Dex 
group: Dex was added in the media at a concentration of 10-6 M, (c) DexR: drug was electrically released in PBS 
from PPy-Dex electrode and the resulting solution was added to media with the final Dex concentration of 10-6 M, 
(d) Graph showing the normalized number of astrocytes on day 3 for control (Ctrl), added Dex (Dex) and released 
Dex (DexR) (n=6, ±SEM).  Significant reduction in the number of astrocytes in both Dex and DexR media, when 
compared to Ctrl (* p<0.001 for Ctrl and Dex, ** p<0.001 for Ctrl and DexR) while there was no significant 
difference between Dex and DexR.  
 33 
 Figure 11.  In-vitro studies for the effect of released Dex on astrocytes and microglia 
The red color is M1/70 staining for microglia and the green is GFAP staining for astrocytes.  The nuclei are stained 
using Hoechst dye.  (a) Control group: no drug, (b) Dex group: drug was electrically released in PBS from PPy-Dex 
electrode and the resulting solution was added to media with the final Dex concentration of 10-6 M.  For this one 
time experiment (n=3 samples per condition, 6 images on each sample), lowered glial cell count (astrocytes and 
microglia) was observed.   
 34 
 Figure 12.  Effect of Dex on neuron viability on day 3 of culture. 
In-vitro cultured neurons were stained using β-tubulin and Hoescht dye.  Scale bar is 50 µm.  Co-localization of β-
tubulin and Hoescht was used to identify neurons.  Neurite measurement, using MetaMorph TM software, enabled 
identification of healthy neurons as those with at least one neurite.   There is no significant difference between the 
three groups.   
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5.0  CONCLUSION 
In this study, we have successfully developed a polypyrrole based electrode coating for 
electrically controlled and local delivery of an ionic form of dexamethasone (Dex), an anti-
inflammatory synthetic glucocorticoid.  An appealing feature of the system is that it allows local 
drug release from individual electrode coatings in a controlled manner.  Initial results show that 
out of a 50 nm thick PPy/Dex film, we are able to release 0.5 µg/cm2 Dex after each CV cycle 
and upto 92% release after 30 CV cycles.  In vitro studies on murine glial cells suggest that the 
released drug effectively reduces the number of reactive astrocytes and microglia.  In addition, 
release of drug from the polymer coating does not produce any toxic side effects as seen by the 
healthy neuronal growth.  In fact, the released drug caused increased neurite formation when 
compared to control.   
In summary, we have established a drug delivery system that allows on-command, 
precise and local release of drugs from neural electrodes.  The release dosage can be controlled 
via controlling the applied electrical stimuli.  The mechanism is not confined to this particular 
polymer-drug system and may be extended to other combinations of conducting polymer and 
suitable dopants.  Furthermore, this system can be easily integrated into any implantable 
electrode device setup, that are used clinically (such as deep brain stimulators and cochlear 
implants) or in a research setting (other neural prosthetic devices that are being actively 
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developed). The electrical command for release control can be conducted via the preexisting 
circuits. 
Further studies can be done to improve the system developed in this project.  The current 
polymer polypyrrole allows consistent release for ~30 CV cycles, following which the film does 
not remain stable.  While such a lifetime maybe sufficient in some applications, one may need to 
improve the stability of the polymer for prolonged release applications.  This may be improved 
in the following ways.  Firstly, an intrinsically more chemically and mechanically stable 
conducting polymer, like polyethylenedioxythiophene (PEDOT) can be selected.  Secondly, the 
mechanical stability of the polymer and adherence between polymer and electrode substrate 
maybe enhanced.  For example, addition of filler molecules or physical crosslinkers could 
stabilize the polymer film.  To increase the adherence between the polymer and electrode 
substrate, modifications on the surface and in the original monomer can be done, which in turn 
help to form covalent binding between the polymer and electrode surface [55].  Alternatively the 
adherence can be improved by roughening the surface of the electrode [56].   
The next ideal step after in-vitro cell culture studies would be to study the release of the 
drug in vivo from implanted neural devices.  While our CV and Dex release data suggests that 
most of the dex was incorporated as dopants and will not be released without electrical 
perturbance, we can not exclude the possible material degradation in vivo in long term which 
could lead to release without electrical command. This may be evaluated through in vivo 
degradation study. 
   Another aspect worth investigating would be how to increase drug load and the release 
efficiency.  Research has shown [57, 58] that it is possible to electrochemically synthesize 
conducting polymers inside a  hydrogel support matrix.  Such a matrix offers the obvious 
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advantages of higher water content and surface area due to 3D porous nature which allow more 
drug incorporation and faster release.  Surface area can also be greatly enhanced by creating 
nano-fibrous morphology through various nano-templating techniques [59-61].   
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